Carlisle Companies Incorporated operates as a manufacturer and supplier of building envelope products and solutions in the United States, Europe, North America, and internationally. It operates ...

Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

CSL is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in ...

Three years after introducing Hemgenix, the first gene therapy for hemophilia B, CSL Behring has released long-term data proving the treatment’s benefits remain durable after five years. The five-year ...

CSL shares are currently trading near a 7-year low. CSL shares have been under pressure, trading near $180, due to softer profits, rising costs, and slow plasma business recovery. Despite recent ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines committee ...

Australia's CSL, which earlier this year paused plans to put its CSL Seqirus vaccine division up for sale, has opened the doors to a new $1 billion cell-based influenza vaccine and antivenom ...